Program overview
Context
Indication: Gastric Cancer (GC)
Mechanism: Unknown
Modality: Unknown
Sponsor: Qilu Pharmaceutical Co., .
Operational Burden Signal
QLS5132; Bevacizumab
QLS5132; Bevacizumab is flagged as operational burden signal because public records show operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 0/5
Timeline: 0/5
Recruitment burden: 3/5
Results availability: 0/5
Program risk: 2/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT07453394
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT07453394 | Low Signal (NOT_YET_RECRUITING) | None | Low Signal | large_enrollment_target_signal | few_sites_large_trial_signal | strict_eligibility_signal |